Pulmonary Embolism Clinical Trial
— SEATTLE IIOfficial title:
A Prospective, Single-Arm, Multi-Center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE)
Verified date | July 2021 |
Source | Boston Scientific Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right ventricle (RV) to left ventricle (LV) diameter within 48 =/- 6 hours in participants with massive or submassive PE.
Status | Completed |
Enrollment | 150 |
Est. completion date | February 17, 2013 |
Est. primary completion date | February 17, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Computed tomography (CT) evidence of proximal PE (filling defect in at least one main or segmental pulmonary artery) - PE symptom duration less than or equal to (<=)14 days - Informed consent can be obtained from participant or Legally Authorized Representative (LAR) - Massive PE (syncope, systemic arterial hypotension, cardiogenic shock, or resuscitated cardiac arrest) or - Submassive PE (RV diameter-to-LV diameter greater than or equal to [>=] 0.9 on contrast-enhanced chest CT) Exclusion Criteria: - Stroke or transient ischemic attack (TIA), head trauma, or other active intracranial or intraspinal disease within one year - Recent (within one month) or active bleeding from a major organ - Hematocrit less than (<) 30 percent (%) - Platelets < 100 thousand/microliter (mcL) - International Normalized Ratio (INR) greater than (>) 3 - Activated partial thromboplastin time (aPTT) >50 seconds on no anticoagulants - Major surgery within seven days of screening for study enrollment - Serum creatinine >2 milligrams/deciliter (mg/dL) - Clinician deems high-risk for catastrophic bleeding - History of heparin-induced thrombocytopenia (HIT) - Pregnancy - Catheter-based pharmacomechanical treatment for pulmonary embolism within 3 days of study enrollment - Systolic blood pressure less than 80 mm Hg despite vasopressor or inotropic support - Cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (CPR) - Evidence of irreversible neurological compromise - Life expectancy <30 days - Use of thrombolytics or glycoprotein IIb/IIIa antagonists within 3 days prior to inclusion in the study - Previous enrollment in the SEATTLE study |
Country | Name | City | State |
---|---|---|---|
United States | Inova Alexandria Hospital | Alexandria | Virginia |
United States | Montefiore Medical Center | Bronx | New York |
United States | Mt. Carmel East | Columbus | Ohio |
United States | Providence Memorial and Sierra Medical Center | El Paso | Texas |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | Hartford Hospital | Hartford | Connecticut |
United States | St. Vincent Hospital | Indianapolis | Indiana |
United States | Lakeland Regional Medical Center | Lakeland | Florida |
United States | University of Kentucky, Gill Heart Institute | Lexington | Kentucky |
United States | Medical Center of Central Georgia | Macon | Georgia |
United States | Holmes Regional Medical Center | Melbourne | Florida |
United States | Memorial Medical Center | Modesto | California |
United States | Baptist Health | Montgomery | Alabama |
United States | Overlook Medical Center | Morristown | New Jersey |
United States | East Jefferson General Hospital | New Orleans | Louisiana |
United States | Christiana Hospital | Newark | Delaware |
United States | Florida Hospital | Orlando | Florida |
United States | Orlando Regional Medical Center | Orlando | Florida |
United States | The Miriam Hospital | Providence | Rhode Island |
United States | Prairie Heart Institute | Springfield | Illinois |
United States | Stanford University Medical Center | Stanford | California |
United States | Holy Name Hospital | Teaneck | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Boston Scientific Corporation | EKOS Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio Within 48 +/- 6 Hours of Initiation of Therapy | Change from baseline in RV diameter/LV diameter ratio was determined by contrast-enhanced chest computed tomography (CT) within 48 +/- 6 hours after initiating ultrasound-accelerated catheter-directed fibrinolysis. | Baseline, within 48 +/- 6 hours of initiation of therapy | |
Primary | Number of Participants With Major Bleeding | Bleeding adverse events were graded (severe or life-threatening, moderate or mild bleeding) according to the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification. The participant incidence of major bleeding events was defined as GUSTO moderate and severe events occurring within 72 hours after starting the ultrasound-accelerated catheter-directed fibrinolysis procedure. Mild: Does not meet criteria for moderate or severe; Moderate: Requires transfusion - No hemodynamic compromise; and Severe: Bleeding causes hemodynamic compromise and required intervention or intracranial hemorrhage. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. | From start of study drug infusion up to 72 hours | |
Secondary | Change From Baseline in Pulmonary Artery Systolic Pressure at 48 Hours After Start of Therapy | Change in pulmonary artery systolic pressure was assessed by baseline right-heart catheterization compared with right-heart catheterization at the conclusion of ultrasound-accelerated catheter-directed fibrinolysis and estimated by post-procedure transthoracic echocardiography within 48 hours after initiating the procedure. | Baseline, Hour 48 after initiation of therapy | |
Secondary | Percentage of Participants With Symptomatic Recurrent Pulmonary Embolism (PE) | Percentage of participants with symptomatic recurrent PE up to 30 days following the conclusion of the ultrasound-accelerated catheter-directed fibrinolysis procedure, were reported with a Wilson score 95% confidence interval. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. | Baseline up to Day 30 | |
Secondary | Number of Participants Who Died Due to Any Cause | Number of participants who died due to any cause for up to 30 days following the conclusion of the ultrasound-accelerated catheter-directed fibrinolysis procedure, were reported. | Baseline up to Day 30 | |
Secondary | Number of Devices That Could Not be Successfully Used for Infusion | Technical complications associated with the use of the EkoSonic device was recorded during catheter placement in the pulmonary artery and during the infusion procedure. | Baseline up to Day 30 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05050617 -
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
|
||
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Completed |
NCT03915925 -
Short-term Clinical Deterioration After Acute Pulmonary Embolism
|
||
Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT04454554 -
Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
|
||
Completed |
NCT03173066 -
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
|
Phase 1 | |
Terminated |
NCT03002467 -
Impact Analysis of Prognostic Stratification for Pulmonary Embolism
|
N/A | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02611115 -
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
|
N/A | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT01326507 -
Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
|
N/A | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT02476526 -
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00780767 -
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
|
Phase 2 | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00816920 -
Natural History of Isolated Deep Vein Thrombosis of the Calf
|